Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Clinical trial NCT04246762 · COMPLETED
Trial details
- NCT number
- NCT04246762
- Sponsor
- R-Pharm International, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-16
- Primary completion
- 2022-06-08
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.